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OBJECTIVES: During 2009-2011 major healthcare reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the US,
AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed re-
form in the UK. These reforms have major implications on pricing, market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2011 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. Stakeholders ranked various data collection
methods on a scale of 1-10 (1-least important and 10-most important). RESULTS:
The global healthcare landscape is expected to undergo significant change during
2012-2016. In the US, government will play increased role as a single payer, espe-
cially with–Medicare, Medicaid and CHIP programs– which will cover 114 million
Americans, at a cost of $784 billion. In Germany, AMNOG bill marked the end of free
drug pricing and would lead to increased insurance premiums (now 15.5% of
wages). In the UK, NHS has proposed to replace PCTs with 500-1000 GP-led consor-
tia and use value-based pricing for expensive drugs and devices. Randomized con-
trolled trial, budget impact model and systematic reviews —ranked highest (7.5-
9.1) among payers. Overall, payers view that in the future, health economic
assessments would play critical role in pricing, coverage and reimbursement of
branded products. CONCLUSIONS: This analysis shows that global healthcare
landscape is expected to undergo significant change during 2012-2016. Discussions
with payers, KOLs and payer-influencers highlights increased importance of HEOR
data in the future.
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OBJECTIVES: Estimate the effect size, by means of odds ratios, of explanatory vari-
ables on the reimbursement decision by the Scottish Medicines Consortium (SMC).
METHODS: SMC submissions between 2008-01-01 until 2011-02-01 were reviewed.
From these, 23 a priori defined predictor variables were extracted. Among these
were “BI“ i.e. high and low net budget impact defined as above £500,000, “certainty-
of-ICER“ defined as an ICER (base-case or sensitivity analysis) above £30,000, “com-
parator” defined as active or placebo/uncontrolled trial and “Childhood disease” i.e.
the application is for a childhood disease or not, with childhood defined as below or
above 18 years of age. The impact of these variables was estimated by means of
odds ratios in univariate and multivariate logistic regression analyses. RESULTS:
Two hundred forty-nine drug applications were reviewed; 151 (61%) received a
positive recommendation and 98 (39%) were rejected by SMC. Based on the univar-
iate analyses the following variables were included in the final multivariate model:
“BI“, “certainty-of-ICER “, “comparator” and “Childhood disease”. The other 19 vari-
ables such as chronic use, negative risk profile, type of endpoint and societal im-
pact were excluded during the backward selection process for the multivariate
model. A positive reimbursement was 47.3:1 more likely for “Childhood disease”
versus “no Childhood disease”, 25:1 for certain versus uncertain ICER, 3.33:1 for
active versus placebo/uncontrolled trial and 2.38:1 for low versus high BI. The
corresponding output (OR [95%CI]) from the regression was (47.3[7.1-961.9]) for
“Childhood disease”, (0.04 [0.01-0.11]) for “certainty-of-ICER “, (0.30 [0.11-0.75]) for
“comparator” and (0.42 [0.16-1.10]) for “BI“. The R2 statistic for the multivariate
model was 0.41 and in-sample prediction was 82%. CONCLUSIONS: Most critical
predictors for reimbursement were uncertain ICER and Childhood disease. Future
research should add granularity by also including reimbursement restrictions as
outcome. External validity should be tested by out of sample predictions for new
drugs.
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OBJECTIVES: Since 2005, reimbursement requests for outpatient drugs claiming
added therapeutic value require pharmacoeconomic evidence to obtain reim-
bursement in the The Netherlands. This study aims to obtain insight into the role
of pharmacoeconomics in actual decision making. METHODS: We studied public
reimbursement reports from 2005 onwards and investigated in detail the role of
pharmacoeconomics next to therapeutic value and budget impact in decision
making. RESULTS: From 2005 - April 2011, the Dutch reimbursement agency eval-
uated 304 dossiers, 186 concerned outpatient drugs of which 113 were submitted
with a claim of added therapeutic value. In total, 26 out of 113 were denied reim-
bursement, 60 were classified having added therapeutic value (Annex 1B), 27 were
clustered with equivalent drugs (Annex 1A). Only 30% of the submissions (18 out of
60 positive 1B decisions) contained pharmacoeconomic evidence; 37%, 12% and
22% were exempted due to orphan status, being a HIV drug, or other unknown
reasons, respectively. Three out of the 18 submissions with pharmacoeconomic
evidence only supplied a cost-minimisation analysis, 4 only a cost-effectiveness
analysis (1 alongside a cost-minimisation analysis); 11 supplied a cost-utility anal-
ysis. Uncertainty was often related to (assumed) treatment utilities and the applied
pharmacoeconomic model, only 9 submissions included a cost-effectiveness plane
and an acceptability curve. Interestingly, 4 (2) submissions were judged as “insuf-
ficiently (moderately) founded” pharmacoeconomic evidence but still received a
positive decision, presumably due to their added therapeutic value, treatment mo-
dality, expected budget impact, or orphan status. CONCLUSIONS: Although cost-
effectiveness is a formal reimbursement criterion in the The Netherlands, only 18
out of 60 positively evaluated submissions contained pharmacoeconomic evi-
dence. Only robustness of evidence is evaluated. Even “insufficiently founded”
evaluations can yield positive reimbursement decisions. Hence, cost-effectiveness
does not seem prominent in actual decision making, resulting in uncertainty about
value for money of currently reimbursed drugs.
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OBJECTIVES: Reimbursement decisions require evidence of effectiveness and a
randomised controlled trial (RCT) is seen as the best study design to demonstrate
effectiveness. However, there may be situations where a (double-blind) RCT will
not be considered necessary, appropriate, methodologically feasible, or ethical.
The aim of this study was to develop a decision algorithm to determine the appro-
priate level of evidence when assessing the effectiveness of a medical intervention.
METHODS: The initial algorithm was based on the literature and interviews with
personnel at the Health Care Insurance Board (CVZ), the central reimbursement
authority in the The Netherlands. In addition to the results of a previous study of 72
reimbursement dossiers concerning medical specialist care, we also retrospec-
tively studied 20 reimbursement dossiers made by CVZ to identify any arguments
why lower level evidence could be accepted. We then interviewed several Dutch
and foreign experts. Our algorithm was continuously refined during the study and
prospectively validated using new reimbursement dossiers. RESULTS: RCT evi-
dence was lacking in most positive reimbursement decisions (8/9), but also in most
negative reimbursement decisions. Methodological issues can play a role in accept-
ing lower levels of evidence, e.g. when blinding is impossible. Moreover, an RCT
may be unsuitable (e.g. due to time constraints) or viewed as unnecessary (e.g. in
testing parachutes). Finally, ethical reasons can play a role in accepting lower level
evidence. Our decision algorithm contains a stepwise approach to determine the
appropriate evidence level, which includes (double-blind) RCTs, observational
comparative effectiveness research or non-comparative effectiveness research.
CONCLUSIONS: Policy regarding acceptance of lower level evidence in reimburse-
ment decisions needs to be transparent. Our decision algorithm can guide decision
makers in reaching a structured and well-founded decision as to whether lower
level evidence of effectiveness is appropriate.
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OBJECTIVES: Clinical trials (CTs) represent important investments in the clinico-
economic setting, as well as in the “human capital” of developed economies. The
purpose of the study was to depict CT activity in Greece for 2010. METHODS: A
questionnaire-based survey was conducted among the members of the Hellenic
Association of Pharmaceutical Companies (SFEE). Each company was requested to
return via email one questionnaire per interventional CT approved by the Hellenic
National Ethics Committee in the year 2010. Items in the questionnaire focused on
the following points: phase of the trial, duration, number of patients, CT sites,
therapeutic area of the agent under survey and planned budget for the study. The
survey lasted for 4 months (December 2010-March 2011). RESULTS: Fifty of the 65
SFEE members returned questionnaires (response rate 77%). The majority of CTs
was phase-III trials (67%), mainly on oncology (26.5%), endocrine disorders (16.4%)
and cardiovascular diseases (13.9%). Most CT sites were affiliated with a university
(46%) or an NHS hospital (46%), enrolling 4.5-7.5 patients, on average, depending on
CT phase. The average budget per CT was 296,600€ (s.d.: 389,948€). In total, 120
interventional CTs were approved in 2010 in Greece, with the total investment
estimated at 35.6 million Euros. CONCLUSIONS: Compared to its European peers,
the number of CTs conducted in Greece is extremely low. Within a global market
context, this constitutes a problem of lost research opportunities and underuse of
the country’s acknowledged scientific capacity. Major hurdles could be identified in
the “bureaucracy” and complexity of the approval process, mainly within NHS, lack
of acknowledgement of CT as key priority for research investment and lack of a
strong framework for health technology assessment. Quick changes are necessary,
in order to cover the distance lost.
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OBJECTIVES: In the public debate surrounding public health and prevention, it is
sometimes assumed that preventive interventions are by definition cost-effective.
This study aims to explore whether preventive pharmaceutical interventions are
more cost-effective than a curative approach to diseases. METHODS: A descriptive
study identified European economic evaluations in the Tufts Medical Center Cost-
A352 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
